Lomerizine
 |
|
|
Lomerizine
|
|
| Systematic (IUPAC) name | |
| 1-[Bis(4-fluorophenyl)methyl]-4-[(2,3,
4-trimethoxyphenyl)methyl]piperazine |
|
| Identifiers | |
| CAS number | 101477-55-8 |
| ATC code | ? |
| PubChem | 3949 |
| Chemical data | |
| Formula | C27H30F2N2O3 |
| Mol. mass | 468.53 g/mol |
| SMILES | eMolecules & PubChem |
| Pharmacokinetic data | |
| Bioavailability | ? |
| Metabolism | ? |
| Half life | ? |
| Excretion | ? |
| Therapeutic considerations | |
| Pregnancy cat. |
? |
| Legal status |
℞ Prescription only |
| Routes | Oral |
Lomerizine (INN) is a calcium antagonist.
 |
This pharmacology-related article is a stub. You can help Wikipedia by expanding it. |
Categories: Pharmacology stubs
Why are we here?
All text is available under the terms of the GNU Free Documentation License
This page is cache of Wikipedia. History